Seventeen women who met the criteria for bulimia nervosa (DSM-III-R) were treated for 4 weeks in an open trial with ipsapirone, a partial 5-HT1A agonist. Bulimic symptoms diminished in 66.6% of the patients after only 1 week of treatment, 93.3% showed a reduction of more than 50% of weekly binge eat...
Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.
No comments yet
Be the first to share your thoughts!